All Outputs (10)

A realist evaluation of a multifactorial falls prevention programme in care homes (2022)
Journal Article
Leighton, P. A., Darby, J., Allen, F., Cook, M., Evley, R., Fox, C., …Logan, P. (2022). A realist evaluation of a multifactorial falls prevention programme in care homes. Age and Ageing, 51(12), Article afac263. https://doi.org/10.1093/ageing/afac263

BACKGROUND: falls in care homes are common, costly and hard to prevent.Multifactorial falls programmes demonstrate clinical and cost-effectiveness, but the heterogeneity of the care home sector is a barrier to their implementation. A fuller appreciat... Read More about A realist evaluation of a multifactorial falls prevention programme in care homes.

Management of secondary central nervous system lymphoma (2022)
Journal Article
Cwynarski, K., Cummin, T., Osborne, W., Lewis, J., Chaganti, S., Smith, J., …the British Society for Haematology (BSH) Committee. (2023). Management of secondary central nervous system lymphoma. British Journal of Haematology, 200(2), 160-169. https://doi.org/10.1111/bjh.18539

Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management (2022)
Journal Article
Tse, E., Fox, C. P., Glover, A., Yoon, S. E., Kim, W. S., & Kwong, Y. L. (2022). Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management. Seminars in Hematology, 59(4), 198-209. https://doi.org/10.1053/j.seminhematol.2022.10.002

Natural killer (NK)/T-cell lymphomas arise mainly from NK-cells and occasionally T-cells, and are universally infected with Epstein Barr virus (EBV). They are uncommon lymphomas more prevalent in Asian and Central/South American populations. NK/T-cel... Read More about Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management.

International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma (2022)
Journal Article
Khwaja, J., Kirkwood, A. A., Isbell, L. K., Steffanoni, S., Goradia, H., Pospiech, L., …Cwynarski, K. (2023). International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma. Haematologica, 108(3), 882-888. https://doi.org/10.3324/haematol.2022.281640

Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma (2022)
Journal Article
Wendler, J., Fox, C. P., Valk, E., Steinheber, C., Fricker, H., Isbell, L. K., Neumaier, S., Okosun, J., Scherer, F., Ihorst, G., Cwynarski, K., Schorb, E., & Illerhaus, G. (2022). Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma. BMC Cancer, 22(1), Article 971. https://doi.org/10.1186/s12885-022-09723-w

Background: Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (PCNSL) is a rare disorder with an increasing incidence over the past decades. High-level evidence has been reported for the MATRix regimen (high-dose methotrexat... Read More about Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.

Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group (2022)
Journal Article
Steffanoni, S., Calimeri, T., Laurenge, A., Fox, C. P., Soussain, C., Grommes, C., …Ferreri, A. J. M. (2022). Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group. British Journal of Haematology, 199(4), 507-519. https://doi.org/10.1111/bjh.18396

To optimise management of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection identifying high-risk patients and maintaining treatment dose intensity is an important issue in patients with aggressive lymphomas. In the present study... Read More about Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group.

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial (2022)
Journal Article
Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., Celico, C., …IELSG32 study investigators. (2022). Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 36(7), 1870-1878. https://doi.org/10.1038/s41375-022-01582-5

219 HIV-negative adults ≤70 years with primary CNS lymphoma (PCNSL) were enrolled in the randomized IELSG32 trial. Enrolled patients were randomly assigned to receive methotrexate-cytarabine (arm A), or methotrexate-cytarabine-rituximab (B), or metho... Read More about Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.

Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study (2022)
Journal Article
Lim, S. H., Stuart, B., Joseph-Pietras, D., Johnson, M., Campbell, N., Kelly, A., …Goldblatt, D. (2022). Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nature Cancer, 3(5), 552-564. https://doi.org/10.1038/s43018-022-00364-3

Patients with hematological malignancies are at increased risk of severe COVID-19 outcomes due to compromised immune responses, but the insights of these studies have been compromised due to intrinsic limitations in study design. Here we present the... Read More about Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study.

Rare central nervous system lymphomas (2022)
Journal Article
Kaji, F. A., Martinez‐Calle, N., Sovani, V., & Fox, C. P. (2022). Rare central nervous system lymphomas. British Journal of Haematology, 197(6), 662-678. https://doi.org/10.1111/bjh.18128

Central nervous system (CNS) lymphomas are rare malignancies characterised by lymphoid infiltration into the brain, spinal cord, cranial nerves, meninges and/or eyes in the presence or absence of previous or concurrent systemic disease. Most CNS lymp... Read More about Rare central nervous system lymphomas.

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients (2022)
Journal Article
Wilson, M. R., Eyre, T. A., Kirkwood, A. A., Wong Doo, N., Soussain, C., Choquet, S., …McKay, P. (2022). Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood, 139(16), 2499-2511. https://doi.org/10.1182/blood.2021014506

Prophylactic high-dose methotrexate (HD-MTX) is often used for diffuse large B-cell lymphoma (DLBCL) patients at high risk of central nervous system (CNS) relapse, despite limited evidence demonstrating efficacy or the optimal delivery method. We con... Read More about Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.